mRNA Vaccines Against Infectious Diseases
A large amount of research has shown that mRNA-based vaccines are a promising novel platform, which is scalable, inexpensive, and cold-chain free. More importantly, mRNA-based vaccines have the potential to fill the gap between emerging pandemic infectious diseases and an abundant supply of effective vaccines. At present, self-amplifying mRNA (SAM) and non-replicating vaccines, two kinds of mRNA-based vaccines have been developed against infectious diseases. They have made promising accomplishments in the infectious disease field, showing safe, potent, and long-lasting immune response in a variety of preclinical and clinical trials.
The advantages of mRNA-based vaccines in the prevention of infectious disease
To date, to prevent and eliminate the transmission of infectious diseases, vaccination might be the most effective among public health interventions. Since the development of vaccination in the 18th century, they have become the basis of global public health programs and major socioeconomic benefits. Although traditional vaccine methods have progressed, factors such as a long development cycle, complex vaccine production, and high investment costs still hinder conventional vaccine platforms. Besides, conventional vaccine technology platforms are inadequate with the need to develop vaccines for chronic infections as well as emerging diseases.
Compared with conventional vaccines, mRNA vaccines show great potential and offer many advantages. The platform of synthetic mRNA is based on a module to deliver a synthetic gene that encodes nanoparticles containing immunogens. Therefore, the major advantage of the platform is universal, adapting a new target disease with minimal changes in chemistry, manufacturing, as well as quality controls. Based on mRNA technologies and a streamlined regulatory process, mRNA vaccine development can focus on the safety and potency of the transcript of interest, available to cope with multiple pathogens.
Preclinical and clinical application of infectious disease mRNA vaccines
The research of synthetic mRNA in the infectious disease field has been rapidly expanding. Multiple preclinical studies have shown that the novel vaccine type is able to fight against viral, bacterial, and parasitic pathogens by inducing protective immune responses. Moreover, comparative preclinical studies have demonstrated that some mRNA vaccines are superior to subunit, live-attenuated, and inactivated pathogens containing vaccines, further suggesting the potential of mRNA vaccines as substitutes of conventional vaccines. Preclinical and clinical applications of mRNA vaccines in infectious diseases are listed below.
-Influenza virus mRNA vaccines
-HIV-1 mRNA vaccines
-Flavivirus mRNA vaccines
-Rabies mRNA vaccines
-Ebola virus mRNA vaccines
-Other viruses, involving herpes simplex virus type 2 (HSV-2), Human cytomegalovirus (HCMV), and Venezuelan equine encephalitis virus (VEEV).
To further promote the development of mRNA vaccines against infectious diseases, Creative Biogene provides a range of customized and inventive solutions, involving the development of influenza mRNA vaccines, anti-parasite mRNA vaccines, mRNA vaccines against HIV as well as the global SARS-CoV-2 pandemic. We are committed to exerting the potential of synthetic mRNA as an important vaccine candidate for infectious diseases, hoping to meet our customers' specific requirements for projects at the preclinical stages. If you are interested in this area, please feel free to contact us. We look forward to providing services for your next project.
- Alameh, M. G.,et al. (2020). "Messenger RNA-Based Vaccines Against Infectious Diseases."
- Zhang, C., et al. (2019). "Advances in mRNA vaccines for infectious diseases." Frontiers in Immunology, 10, 594.